ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2017; 45(4): 15-23 | DOI: 10.5543/tkda.2017.27632

Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials

Rabia Akıllı, Mesut Demir
Department of Cardiology, Çukurova University Faculty of Medicine, Adana, Turkey

Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia and causes mortality in the community. Cardioversion and catheter ablation are frequently used methods for rhythm control. Oral anticoagulants have been used for many years in the prevention of thromboembolic complications in patients with AF. Both cardioversion and catheter ablation have been associated with certain complication risks especially thromboembolism, which can be significantly reduced by adequate anticoagulation. In this review, we discuss the efficacy and safety parameters of continuous rivaroxaban treatment compared with dose-adjusted vitamin K antagonist therapy in patients who were planned to undergo cardioversion and catheter ablation according to the data of X-VERT and VENTURE-AF trials.

Keywords: Nonvalvular atrial fibrillation, cardioversion, catheter ablation, new oral anticoagulants, rivaroxaban

How to cite this article
Rabia Akıllı, Mesut Demir. Pericardioversion and catheter ablation use of rivaroxaban in light of X-VERT and VENTURE-AF trials. Turk Kardiyol Dern Ars. 2017; 45(4): 15-23

Corresponding Author: Mesut Demir, Türkiye
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.